Tresiba insulin degludec regulatory update

EMA's CHMP recommended approval of an MAA from Novo Nordisk for Tresiba insulin degludec to treat Type I and II diabetes. The long-acting insulin analog is under review by FDA, with a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee scheduled for Nov. 8. Tresiba is a long-acting insulin analog. ...